Form 4: CEO Bendheim Sells PAHC Shares Under 10b5-1 Plan

Phibro Animal Health Corp's President and CEO, Jack Bendheim, and BFI Co., LLC, sold Class A Common Stock totaling 3,520 shares through a pre-arranged 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO of Phibro Animal Health Corp, and BFI Co., LLC, reported sales of Class A Common Stock.
• A total of 3,520 shares were sold on November 20, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• One transaction involved 3,459 shares sold at a weighted average price of $41.752, with prices ranging from $41.29 to $42.25.
• Another transaction involved 61 shares sold at a price of $42.32.
• Following these transactions, BFI Co., LLC indirectly holds 46,160 shares, and Jack Bendheim directly holds 16,840 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While insider selling can be a negative signal, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates much of the concern, making it an expected, non-eventful transaction from a market signaling perspective.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, negative information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived as a slight negative signal regarding management's long-term outlook on the stock, though less so than unplanned sales.

Future Outlook

NA

Management Comments

• Jack Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Industry Context

NA

Related Party Transactions

• The transactions involve Jack Bendheim, President and CEO, and BFI Co., LLC, a 10% owner over which Mr. Bendheim exercises voting and dispositive power, making these related party transactions.

Stakeholder Impact

• Shareholders may view the insider selling, even if pre-planned, with slight caution, though the impact is likely minimal given the 10b5-1 plan. No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

The insider sales by CEO Jack Bendheim and BFI Co., LLC were executed under a pre-arranged 10b5-1 trading plan. This indicates a planned divestment strategy rather than a reaction to new, adverse company developments. While insider selling can sometimes be a negative signal, the pre-scheduled nature significantly reduces its bearish implication. The transaction itself is routine for a Form 4 and does not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing does not present new information that would fundamentally alter the company's valuation or outlook.

Keywords

Phibro Animal Health Corp, PAHC, Jack Bendheim, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, Beneficial Ownership